Compare Palo Alto Networks Inc (PANW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Palo Alto Networks Inc trades at $403.12 (market cap $331.76B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Palo Alto Networks Inc is far larger — about 2.6× Vertex Pharmaceuticals Incorporated's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PANW | VRTX | |
|---|---|---|
Market Cap | $331.76B | $128.16B |
Volume | 3,886,927 | 806,603 |
Sector | Technology | Health |
52-Week High | $419.91 | $557.96 |
52-Week Low | $141.67 | $407.37 |
Typical Hold Time | 82 Days | 120 Days |
Enterprise Value | $331.19B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $405.41, down 3.45% today but remains near recent highs, supported by strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth is robust, climbing from $5.5B in 2022 to $9.2B in 2025, though net margins have fluctuated. Positive sentiment is driven by AI-driven cybersecurity demand and platformization strategy gains.
Outlook: PANW offers growth exposure to the expanding cybersecurity market, with AI integration as a key catalyst. Risks include premium valuation multiples, rising costs, and competitive pressures. Analyst consensus is strongly bullish with a $398.70 price target, but investors should weigh high P/S and EV/EBITDA ratios against growth prospects.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
